Bryan G. Helwig is an associate with McDonnell Boehnen Hulbert & Berghoff LLP. Dr. Helwig concentrates his practice on intellectual property law matters, including patent prosecution, as well as providing infringement and patentability analyses in the biotechnology, pharmaceuticals and medical device and diagnostic areas.
Prior to joining MBHB, Dr. Helwig was a principal investigator for the U.S. Department of Defense wherein he directed a research portfolio tasked with developing pharmaceutical and non-pharmaceutical therapies as well as advancement of molecular device technologies that aid Warfighter survival in extreme environments. The integrative research utilized a wide range of molecular biology, protein chemistry and high throughput technologies. In addition, Dr. Helwig has also served as a consultant to Fortune 500 companies advising on scientific validity of labeling claims, product development and labeling of high protein products.
Dr. Helwig’s graduate and post-doctoral work focused on transformation of stem cells, heart failure and alterations in central nervous control of autonomic function. Dr. Helwig is an author of various scientific manuscripts, including publications in Physiological Genomics and Stem Cells.